IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS
QULIPTA is contraindicated in patients with a history of hypersensitivity to atogepant or any of the components of QULIPTA.

WARNINGS AND PRECAUTIONS
Cases, including anaphylaxis, dyspnea, rash, pruritus, urticaria, and facial edema, have been reported with the use of QULIPTA. Hypersensitivity reactions can occur days after administration. If a hypersensitivity reaction occurs, discontinue QULIPTA and institute appropriate therapy.

ADVERSE REACTIONS
The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue/somnolence.

Dosage form and strengths: QULIPTA is available in 10 mg, 30 mg, and 60 mg tablets.

INDICATION

QULIPTA^® (atogepant) is indicated for the preventive treatment of migraine in adults.

Please see full Prescribing Information.

References: 1. Data on file. AbbVie Inc. January 2020-Febuary 2024. 2. Data on file. AbbVie Inc.

© 2024 AbbVie. All rights reserved.
All trademarks are the property of their
respective owners.
US-QLP-240004  01/24